Guardant Health Inc GH

$145.14 +1.86 (1.30%)

Valuation

Market cap
19,383,778,000
Revenue TTM
$982,020,000
Net income TTM
$-416,280,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-42.39%
Debt to equity
-5.45

Trading

Volume
1,498,500
Avg volume
2,003,292
Day's range
$140.12 – $148.30
Shares out
135,286,000
Stochastic %K
32%
Beta
1.67
Analysts
Strong Buy
Price target
$207.21

Price

Company profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect can...

Show more

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
855 698 8887
Website
https://guardanthealth.com
Address
3100 Hanover Street, Palo Alto, United States

Latest news

Stocktwits

med_tech_gal Nov 19, 2:03 AM
$GH currently at $20B MC, do we think this gets to $40B by 2028?
0 replies
AdamBrennan2 Nov 18, 11:23 AM
cigna $CI screens as one of the cheapest names among the big us health insurers, at 8.9x forward earnings it sells health insurance to employers and also runs express scripts, which manages drug benefits for health plans. forward revenue is still expected to grow 4.3%, faster than most of the group to me this looks more like a drug benefit business with an insurer attached than a plain insurer, and i think people price it like the second thing $CVS $LH $DGX $GH
0 replies
The1Albatross Nov 18, 1:47 AM
$GH Think we see something real nice Q1 ;)
0 replies
med_tech_gal Nov 16, 8:21 PM
$GH ugly sell off.
1 replies
Gator5326 Nov 14, 5:25 PM
$CTMX i have rode $GH from $16 to where its at today. i believed in it and held theough all the games knowing, through my DD, the company was solid. i feel just as strong about CTMX. unless something changes i will be adding through Dec! GLTA
1 replies
dustlesspuma Nov 13, 7:22 PM
🔴 $GH 140P Jun 17 💰 $479,600 premium 💵 $0/contract 📊 0x Vol/OI 📍 Spot $479.6 💰 Large premium 🌊 Dark Flow | Options Flow
0 replies
OpenOutcrier Nov 12, 1:35 PM
$GH (+1.4% pre) GH Q3 2026 deep dive: new product launches and coverage wins drive growth, but market cautious on profitability https://ooc.bz/l/120980
0 replies
Gator5326 Nov 12, 11:21 AM
$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyf7-2BfqgDTPA1pwQgPEK0LIA-2FTvqYJEq10x7ZGmLPHUcUeY-2BuAVaCJ6rcDG5R6-2BSrrUrMvglLVlar56Z2XBeUlfUmL9wAO3H6XG-2FuABIhn-2B1pzJfwv-2FOUprL2Zco4884egI-3DlyYX_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHRgIG36Opi-2BfPD0wkS0BpMvIvciYFROOXXphfdb9zvz3b3UNVGLtyFeBfFmXrFXLVyTc2klPP5De-2FidavnGbV03Wl80164A3qG-2BBpP-2Fbg-2BvN31g7-2Bcly7NsI2ak9n7DyysJiU1vM3vVyUwv3MWcB3YXhOwJg08ohVmIuqryXWxkBG8WTr7M9FM-2B-2FhBKPXp1qdV-2BNTAOe8B5Hl8O75l0-2BhTZoNky-2FCej9w48ccfYkAEIrPkipbpUci619FKFizQpq6TcqMh-2BpZRfDZsEwB76bMbw-3D-3D
0 replies